|
Characteristic
|
LRFS
|
OS
|
|---|
| |
HR (95% CI)
|
p
|
HR (95% CI)
|
p
|
|---|
|
Age (y)
| | | | |
|
≤ 35 vs. > 35
|
1.664 (1.082-2.558)
|
0.020*
|
—
| |
|
Menopausal status
| | | | |
|
Pre- vs. postmenopausal
|
1.623 (1.106-2.383)
|
0.105
|
—
| |
|
Tumor size
| | | | |
|
T3-4 vs. T1-2
|
1.636 (1.029-2.600)
|
0.037
|
1.392 (0.917-2.113)
|
0.121
|
|
ER status
| | | | |
|
Negative vs. positive
|
1.536 (1.095-2.155)
|
0.013*
|
1.054 (0.699-1.590)
|
0.802
|
|
PR status
| | | | |
|
Negative vs. positive
|
1.626 (1.148-2.302)
|
0.317
|
1.490 (1.040-2.136)
|
0.030*
|
|
HER-2-neu status
| | | | |
|
Positive vs. negative
|
—
| |
1.208 (0.888-1.644)
|
0.228
|
|
Hormone therapy
| | | | |
|
None vs. yes
|
1.180 (0.731-1.904)
|
0.498
|
1.570(1.093-2.255)
|
0.015*
|
|
Lymph node ratio
| | | | |
|
< 0.20
|
1 (Reference)
| |
1 (Reference)
| |
|
0.21-0.65
|
1.886 (1.273-2.794)
|
0.002*
|
1.964 (1.387-2.782)
|
<0.001*
|
|
> 0.65
|
5.013 (3.191-7.877)
|
<0.001*
|
7.381 (5.161-10.557)
|
<0.001*
|
|
Number of positive lymph nodes
| | | | |
|
pN1
|
1 (Reference)
| | | |
|
pN2
|
0.828 (0.476-1.442)
|
0.522
|
1.327 (0.808-2.179)
|
0.263
|
|
pN3
|
0.894 (0.437-1.828)
|
0.907
|
1.654 (0.904-3.027)
|
0.103
|
- LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor family 2; HR, Hazard ratio; CI, Confidence interval.
- *p<0.05 indicates a significant difference.
